- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Efficacy End Points For PNH Treatment
Dr Haumschild continues leading an expert discussion surrounding key strategies and pain points in PNH treatment.
EP: 1.PNH Overview and Pathophysiology
EP: 2.Intravascular and Extravascular Hemolysis MoA in PNH
EP: 3.Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming
EP: 4.Key Treatment Considerations for Patients Diagnosed With PNH
EP: 5.Complement System Role in PNH Treatment Approach
EP: 6.Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management
EP: 7.Efficacy End Points For PNH Treatment
EP: 8.Efficacy and Safety Trials Results of Complement Inhibitors
EP: 9.Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration
EP: 10.Investigational Therapies Paving New PNH Treatment Pathways
EP: 11.Key Financial Factors Associated With Typical PNH Treatment Journey
EP: 12.Navigating Transfusion Requirements in PNH Treatment
EP: 13.Considerations for Managing PNH Treatment Complications
EP: 14.Infection Risk Management Counseling For Patients Receiving Treatment for PNH
EP: 15.Ensuring PNH Treatment Access and Adherence to Therapies
EP: 16.Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway
Video content above is prompted by the following:
- Please describe the significance of the different efficacy end points explored for paroxysmal nocturnal hemoglobinuria treatments (eg, lactate dehydrogenase levels, hemoglobin concentrations, absolute reticulocyte count (ARC) levels, transfusion avoidance, Functional Assessment of Chronic Illness Therapy–Fatigue).
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link
November 21st 2024A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Read More
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
